Overall rank by patents
#24,801
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, active 2015–2018. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
Medtronic holds 11 US patents across 3 technology areas, rank #24,801 of 50,000 tracked assignees.
Medtronic Corevalve Llc has been granted 11 US utility patents between 2015 and 2018, placing Medtronic Corevalve Llc at rank #24,801 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.3 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Medtronic Corevalve Llc is one of the more focused assignees in the PatentsView dataset. By volume, Medtronic sits between Maxitrol Company (11 patents, rank #24,797) and Meridian Innovation Pte Limited (11 patents, rank #24,805) - the closest US assignees by grant volume. The composite Innovation Score of 22.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 11 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Medtronic Corevalve Llc's 12.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Medtronic Corevalve Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Maxitrol Company
11 patents
Med-Genesis, LLC
11 patents
Medical Specialties, Inc.
11 patents
Medovex Corp.
11 patents
Meetup, Inc.
11 patents
Meike Technology (Beijing) Ltd.
11 patents
Merge Labs Inc.
11 patents
Meridian Innovation Pte Limited
11 patents
Medtronic CoreValve LLC
11 patents
What this shows Medtronic holds 11 patents at rank #24,801, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Medtronic's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
22 Top 90% higher than 10% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 7 | 63.6% |
| 2016 | 3 | 27.3% |
| 2018 | 1 | 9.1% |
Top 3 of 3 technology areas
Overall rank by patents
#24,801
Across all tracked assignees
22.1 out of 100
How to use this portfolio
Medtronic's 11 grants land it in the top 90% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.